Indigo Diabetes Appoints Paul Moraviec as Chairman of the

0
490

Indigo Diabetes appoints Paul Moraviec as chairman of the board

  • Has decades of leadership experience in the global medtech sector
  • As CEO of ConvaTec Group Plc, he led the $ 4.5 billion IPO on the London Stock Exchange
  • Rebuilding Abbott’s EMEA Diabetes Care department

BELGIUM – Ghent, May 122021 – Indigo Diabetes NV (“Indigo” or the “Company”), a pioneering developer of nanophotonics medical solutions, is pleased to announce the appointment of Paul Moraviec as Chairman of the Board of Directors.

Paul has more than three decades of global healthcare experience and has held multiple leadership positions. Most recently, Paul was Chief Executive Officer of ConvaTec Group Plc, a global medical products and technology company that coordinated a successful turnaround and subsequent $ 4.5 billion IPO on the London Stock Exchange in 2016 in Europe.

He also brings highly relevant diabetes experience to the table after serving as Vice President of Abbott’s Diabetes Care International business from 2002 to 2007 where he transformed the EMEA business into the fastest growing glucose monitoring company with low single digit growth and declining market share.

Paul also led early stage surgical robotics company Prosurgics and redesigned its product development and commercialization strategy. and led an extensive restructuring and performance improvement program in the UK, Germany and France for Johnson & Johnson’s neurosurgery business.

Paul will replace Harrold van Barlingen, who will step down as chairman and retain a seat on the board of directors as non-executive director.

Dr. Danaë Delbeke, CEO, inventor, and co-founder of Indigo Diabetes commented: “We are very excited to have Paul as CEO of Indigo. His experience leading and transforming the business of medtech companies will be invaluable as we further develop our subcutaneous CMM (Continuous Multi Metabolite Monitoring) device. His appointment underscores our business potential and reflects Indigo’s commitment to making our device commercially available for people with diabetes as soon as possible.

“We would also like to thank our outgoing Chairman Harrold van Barlingen, who has made a significant contribution to Indigo and our success to date. We are grateful that we can retain his expertise as a board member.”

Paul Moraviec, Chairman of Indigo Diabetes commented: “I am very excited to join and chair the Indigo Board of Directors and look forward to helping the team successfully execute the strategy and lead the development of its CMM machine, an innovative, next-generation approach to continuous Monitoring of Metabolites for People with Diabetes. ”

– Ends –

About Indigo Diabetes NV
Indigo Diabetes NV (Indigo) is a pioneering developer of medical solutions using nanophotonics. Indigo was founded in 2016 by Danaë Delbeke and her team. Today Indigo is developing the world’s first invisible sensor for people with diabetes to meet their need for continuous accurate glucose and ketone monitoring with an enhanced user experience. Indigo leverages the breakthrough photonics technology that revolutionized the internet to transform diabetes management. Indigo is based in Ghent, Belgium. More information is available at www.indigomed.com.

About the Indigo Diabetes CMM sensor
The Indigo Diabetes CMM sensor is a small spectrometer on a chip for simultaneous and continuous monitoring of multiple metabolites in vivo. The inert, miniaturized integrated silicon photonics spectrometer chip measures the absorption of light in the interstitial fluid to quantify the concentration of multiple metabolites simultaneously without the use of enzymes or fluorophores. Once inserted under the skin, the CMM sensor is invisible to the naked eye and creates a secure and wireless connection to mobile devices to display and record the concentration profiles of the metabolites for the user. A rechargeable sensor battery supplies the measurements with power. The sensor is expected to have a lifespan of up to 2 years. Preclinical studies have successfully demonstrated proof of concept with promising accuracy.

contacts

Indigo Diabetes NV
Dr. Danaë Delbeke, CEO
Email: info@indigomed.com

Financial communication
The design strategic communication
Ashley Tapp, Alexandra Harrison and Priit Piip
Tel .: +44 (0) 20 3709 5700
Email: indigodiabetes@consilium-comms.com